Chlamydia pneumoniae, an obligate intracellular pathogen, is well-known as etiological agent of acute respiratory infections; the repeated or prolonged exposure to chlamydial antigens may promote the persistence of C. pneumoniae in the respiratory tract leading to chronic diseases, such as chronic obstructive pulmonary disease and asthma. The predilection of C. pneumoniae to cause respiratory tract infections combined with its persistent nature suggest that it might playa role in lung cancer. The aim of our study is to evaluate the involvement of C. pneumoniae in pathogenesis of lung cancer. We therefore investigated the presence of C. pneumoniae DNA in tumor lung tissues by using real-time PCR assay. Simultaneously, tumor and healthy tissues from the same patient with primary carcinoma lung were analyzed. C. pneumoniae DNA was not detected in a single lung tumor tissue by means of an highly sensitive, and specific real-time PCR assay based on FRET hybridization probes. In conclusion, this study does not support the involvement of C. pneumoniae in the pathogenesis of lung cancer, suggesting that further investigations are needed to clarify other potential causative factors for the development of this malignancy.
Chlamydia pneumoniae, an obligate intracellular pathogen, is well-known as etiological agent of acute respiratory infections including sinusitis, bronchitis and pneumonia (1) . The repeated or prolonged exposure to chlamydial antigens may promote the persistence of C. pneumoniae in the respiratory tract leading to chronic diseases, such as chronic obstructive pulmonary disease and asthma (2) .
Recently, C. pneumoniae has been associated with other chronic diseases such as multiple sclerosis (3) (4) , Alzheimer's disease (5) , atherosclerosis (6-7), and lung cancer (8) .
The predilection of C. pneumoniae to cause respiratory tract infections combined with its persistent nature (9) suggest that it might play a role in lung cancer (10) ; it is known that chronic infections predispose to malignant growth (11) (12) .
Chlamydial persistence is a key concept in the pathogenesis of lung cancer since C. pneumoniae is able to stimulate an inflammatory response. Indeed in vitro studies demonstrate that C. pneumoniae infection readily induces production of reactive oxygen species, tumor necrosis factor-a, IL-IB, and IL-8 in alveolar macrophages (13) . These mediators of inflammation then cause lung tissue and DNA damage. The subsequent cell division that occurs during repair of the damaged tissue may increase the risk of malignant transformation of infected cells (14) . Therefore, chronic inflammation associated with chronic C. pneumoniae infection has long been considered a risk factor in the development of malignancy (8) .
Several studies on the association between C. pneumoniae infection and lung cancer have been published. All studies report elevated relative risk estimates for the association of serologic evidence of infection and risk of lung cancer (10, 12, (15) (16) (17) (18) (19) (20) . It is likely that early studies concerning the association between C. pneumoniae and atherosclerosis were based on seroepidemiological data (7, (21) (22) . However, several limitations among serological studies were clear in atherosclerosis as well as lung cancer (7) (8) . The majority of these studies used micro immunofluorescence (MIF) that is considered by the CDC to be the reference standard for serodiagnosis, despite the poor specificity and reproducibility (23) . Lastly, the interpretation of serologic results is problematic since a large part of the population has pre-existing antibodies to C. pneumoniae from previous exposure(s) and,hence, it is difficult to identify differences in seropositivity between patients and controls (23) .
Owing to difficulties with serological analysis, nucleic acid amplification assay has been developed as important method for detecting C. pneumoniae. Indeed, the detection of chlamydial DNA by polymerase chain reaction (PCR) has contributed significantly in demonstrating the association of C. pneumoniae with atherosclerotic cardiovascular disease (7, (24) (25) (26) (27) . Therefore, we believe that direct detection of C. pneumoniae in tumor lung tissue is needed to support its involvement in the pathogenesis oflung cancer.
The aim of our study is to investigate the presence of C. pneumoniae DNA in tumor lung tissues by using real-time PCR assay. Simultaneously, tumor and healthy tissues from the same patient with primary carcinoma lung were analyzed.
MATERIALS AND METHODS
Between May and September 2007, 28 consecutive patients with primary lung carcinoma were enrolled. Information on demographic factors, general health and smoking history of each patient was collected.
Lung biopsy specimens were obtained from each patient during surgery and embedded in paraffin. 50 11m section oftumor tissue and 50 11m section of healthy tissue adjacent to the tissue affected were analyzed by real-time PCR for the presence of C. pneumoniae DNA.
Paraffin-embedded sections were deparaffinized with xylene and rehydrated with alcohol. DNA was extracted from each section by using a QIAamp DNA Micro kit (Qiagen) according to the manufacturer's instructions. Genomic DNA was stored at -20°C until used as template in PCR assays. In order to minimise the risk of false-positive results, negative reagent controls obtained replacing clinical specimens with an equal volume of ultrapure water PCR grade were both included and processed throughout the whole extraction procedure. DNA extracted was analyzed by real-time PCR.
LightCycler Control kit DNA was used for quality control of the DNA extracted from clinical specimens. The kit provides all components for the amplification and specific detection of a 110 bp fragment of the humañ -globin gene.
In addition, paraffin-embedded C. pneumoniae infected epithelial line (HEp-2) (ATCC CCL 23) was used for quality control of target DNA. Briefly, HEp-2 cells containing C. pneumoniae VR 53592 (ATCC AR-39) were cultured in Dulbecco's Modified Eagle's Medium containing glucose (4 giL), L-glutamine, and supplemented with 2% fetal calf serum and I ug/ml cycloheximide.
The study was approved by the Medical Ethical Committee of our Institution and all subjects gave written informed consent.
Real-time rc«
Detection and quantification of C. pneumoniae DNA were performed by real-time PCR assay, as previously described (28) . Briefly, real-time PCR assay was based on FRET hybridization probes (CPI-Flu and CPI-LC were purchased from TIB Molbiol and were labeled with fluorescein and LC-Red 705, respectively) and LightCycler instrument (Roche Diagnostics, Germany). PCR primers and probes target an internal 128 bp region of C. pneumoniae PstI species-specific fragment. LightCycler PCR reaction mixtures were carried out in a final volume of 20 III and contained approximately 150 ng of DNA (in a volume I to 5 Ill). All PCR experiments included the melting curve analysis of hybridization probes to assess the specificity of PCR products. Only specimens with a melting temperature 60.8°C were identified as positive. A recombinant plasmid carrying the specie-specific PstI 
RESULTS
The characteristics of patients with primary carcinoma lung are shown in Table I . Our study included 10 men and 18 women with a mean age of 63 ± 6 years. The duration of smoking before the diagnosis of primary lung carcinoma was between 8 and 55 years with a mean of 25 years. Five (18%) of 28 patients had a history of chronic bronchitis or emphysema. The most common histologic type was squamous cell carcinoma (57%) followed by adenocarcinoma (36%) and large cell carcinoma (7%).
A total of 56 lung tissue specimens, 28 tumor tissues and 28 healthy tissues, one healthy specimen and one tumor specimen being obtained from each patient with primary carcinoma lung, were examined for the presence of C. pneumoniae DNA by real-time PCR based on FRET hybridization probes. C. pneumoniae DNA was not detected in single lung tissue by means ofprobe-based, highly sensitive, and specific real-time PCR assay (Fig. 3) .
Our results are true negative since several controls were performed. Firstly, it was examined whether the extracted DNA from paraffin embedded tissues was suitable for analysis by PCR; a 110 bp fragment of the human p-globin gene was amplified by all lung tissue specimens. Secondly, a 128 bp C. pneumoniae species-specific fragment was amplified in infected Hep-2 cells. Thirdly, all real-time PCR analyses were fragment of C. pneumoniae was generated (by cloning the PCR fragment into pOEM T-easy vector; Promega). Ten-fold serial dilutions (from 10 6 to 10 1 copies) of the recombinant plasmid previously characterised were used as standards in quantitative experiments. The PCRnegative control (ultrapure water PCR grade), the dilution series of recombinant plasmid (standard), DNA specimens and the DNA negative extraction controls were analyzed in triplicate in each PCR run. PCR fluorescence profiles were measured at 705 nm (F3 channel) and analyzed with LightCycler software with the F3/F I mode which filters away the background signal of FI channel (Fig. I) . For the quantitative interpretation of the LightCycler results the "fit point method" algorithm was used. A calibration curve was generated from amplification of standard serial dilutions, and threshold cycle (Ct) values were determined in triplicate and plotted against plasmid copy number (Fig. 2) . A specimen was considered positive if all of three assay results were positive in the replicate test. 
DISCUSSION
Several studies have been published study ing a possible association of C. pneumoniae and lung cancer. The evidence for C. pneumoniae as a potential causative agent for lung cancer was based solely on serological findings (8) . The relation ship between C. pneumoniae infection and lung cancer may be correlated to characteristic features of this pathogen, including intracellular growth and ability to induce persistent forms. C. pneumoniae persistent forms are inherentl y more suited to evade the host immune response and are more difficult to eradicate by antibiot ics. Thus, the persistent forms may favour the development of chronic infection and, hence , pathoph ysiological changes leading to lung cancer.
On the other hand, C. pneumoniae stimulates the release of inflammatory mediators and may therefore cause a chronic inflammation resulting in cell death and increased mitotic activity (20) . In contrast to studies already published in the field of C. pneumoniae and lung cancer, this, to our knowledge, is the first study investigating the presen ce of C. pneumoniae DNA in tumor lung tissue.
Our findings do not support the hypothesis that C. pneumoniae is independently associated with lung cancer; C. pneumonia e DNA was not detected in a single lung tissue from patients with primary lung carcinoma despite using a highly sensitive, and specific real-time PCR assay (28) . The real-time PCR has gained wider acceptance for microbiological diagnosis and provides numerous advantages such as closed, automated, nonnested system, including amplification and product detection in a single step, minimizing the risk of cross-contamination.
Possible explanations for these negative findings are the poor-quality of DNA extracted from paraffinembedded tissues and the presence ofPCR inhibitors within tissue specimens. In our study, a 110 bp fragment of the human j3-globin gene was amplified from all clinical DNA specimens confirming the quality of DNA extracted from tumor lung tissues. Furthermore, false-negative PCR results caused by the presence of PCR inhibitors were not very likely because each tissue specimens was checked for inhibitors.
In conclusion, this study does not support the involvement of C. pneumoniae in lung cancer, and further investigations are needed to clarify other potential causative factors for the development of this malignancy.
